文献速递精神分裂症与精神病性障碍

氯氮平与第二代抗精神病药治疗难治性精神分裂症的疗效:系统综述与个体患者数据荟萃分析

Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2025-02-26

该系统综述与个体患者数据荟萃分析纳入19项盲法随机对照试验共1599例难治性精神分裂症患者,其中12项试验1052例获得个体患者数据。治疗6-8周后,氯氮平与其他第二代抗精神病药相比PANSS总分变化均差为-0.64分(95%可信区间-3.97至2.63),方向有利于其他第二代抗精神病药,证据质量极低。作者认为该结果未提供氯氮平疗效优于其他第二代抗精神病药的证据,鉴于氯氮平的副作用,观察到的关于其优越性的不确定性需要谨慎使用和进一步研究。

要点

  • 氯氮平与其他第二代抗精神病药治疗6-8周后PANSS总分变化均差为-0.64分(95%CrI -3.97至2.63),方向有利于其他第二代抗精神病药。
  • 病程较短和基线严重度较高是与症状更大程度减轻相关的预后因素,但未发现这些因素或性别修饰氯氮平与其他第二代抗精神病药的相对效应。
  • 证据质量被评定为极低,作者认为未提供氯氮平疗效优于其他第二代抗精神病药的证据。

核心结论

  • 该个体患者数据荟萃分析发现其他第二代抗精神病药(主要为奥氮平和利培酮)具有小幅且不确定的优势,因此未提供氯氮平疗效优于其他第二代抗精神病药治疗难治性精神分裂症的证据。
  • 鉴于氯氮平的副作用,观察到的关于氯氮平优越性的不确定性需要谨慎使用和进一步研究。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,检索Cochrane精神分裂症组研究注册库从建库至2024年1月24日及既往综述中的盲法随机对照试验。
  • 纳入标准为难治性精神分裂症患者且试验持续时间至少6周;共筛选13876条文献,纳入19项研究共1599例参与者,其中12项试验(n=1052)获得个体患者数据。
  • 获得个体患者数据的1052例中,平均年龄37.67岁(SD 11.24;范围10-66),女性348例(33.08%),男性704例(66.92%);种族数据不可用。
  • 采用贝叶斯随机效应个体患者数据荟萃回归模型,纳入病程、基线严重度和性别作为潜在预后因素或治疗效应修饰因子;证据确定性采用GRADE评估。
  • 研究已在PROSPERO注册(CRD42021254986),并有精神疾病亲历者参与。

主要发现

  • 主要结局为治疗6-8周后PANSS总体症状评分较基线的变化,氯氮平与其他第二代抗精神病药的估计均差为-0.64分(95%CrI -3.97至2.63;τ=2.68),方向有利于其他第二代抗精神病药。
  • 病程较短和基线严重度较高是与症状更大程度减轻相关的预后因素,但未发现这些因素或性别修饰氯氮平与其他第二代抗精神病药之间的相对效应。
  • 证据确定性被评定为极低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 部分研究缺乏个体患者数据。
  • 存在未捕获的方差来源。
  • 因研究提前终止导致不确定性。
  • 证据确定性被评定为极低。
  • 鉴于氯氮平的副作用,观察到的关于氯氮平优越性的不确定性需要谨慎使用和进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clozapine is recommended by national and international guidelines for people with treatment-resistant schizophrenia. However, available meta-analyses of randomised controlled trials have not shown superior efficacy of clozapine when compared with other second-generation antipsychotics, with heterogeneity identified between the original studies. We aimed to use individual patient data (IPD) to account for potential reasons of variability and to synthesise an adjusted estimate for the difference in efficacy between clozapine and other second-generation antipsychotics for treatment-resistant schizophrenia. METHODS: In this systematic review and IPD meta-analysis, we searched the Cochrane Schizophrenia Group's Study-Based Register from inception to Jan 24, 2024, and previous reviews for blinded randomised controlled trials comparing clozapine with other second-generation antipsychotics in participants with treatment-resistant schizophrenia. Trials were eligible if they included patients with treatment-resistant schizophrenia and had a duration of at least 6 weeks. IPD were requested from trial investigators. The primary outcome was change in overall schizophrenia symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) between clozapine and other second-generation antipsychotics after 6-8 weeks of treatment. The effect size measure for the primary outcome was mean difference with 95% credible interval (CrI). We fitted a Bayesian random-effects IPD meta-regression model that included duration of illness, baseline severity, and sex as potential prognostic factors or treatment effect modifiers. Confidence in the evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). People with lived experience of mental illness were involved in this study. This study is registered with PROSPERO, CRD42021254986. FINDINGS: We screened 13 876 references and included 19 studies with data for 1599 participants; IPD were available for 12 of 19 trials (n=1052; mean age 37·67 years [SD 11·24; range 10-66]; 348 [33·08%] women and 704 [66·92%] men). Data on ethnicity were not available. The estimated mean difference in change from baseline PANSS total score was -0·64 points (95% CrI -3·97 to 2·63; τ=2·68) in favour of other second-generation antipsychotics. Shorter duration of illness and higher baseline severity were prognostic factors associated with a larger reduction in symptoms, but neither those factors nor sex were found to modify the relative effect between clozapine and other second-generation antipsychotics. The confidence in the evidence was graded as very low. INTERPRETATION: This IPD meta-analysis found a small and uncertain advantage of other second-generation antipsychotics, mainly olanzapine and risperidone, and so did not provide evidence for superior efficacy of clozapine compared with other second-generation antipsychotics in treatment-resistant schizophrenia. It is limited by unavailability of IPD for some studies, uncaptured sources of variance, and uncertainty due to premature study discontinuation. Given the side-effects of clozapine, the observed uncertainty regarding clozapine's superiority warrants prudent use and further research. FUNDING: German Ministry of Education and Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schneider-Thoma J, Hamza T, Chalkou K, et al. Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis. Lancet Psychiatry. 2025. PMID: 40023172. doi:10.1016/S2215-0366(25)00001-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。